These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models. Ferreira N; Saraiva MJ; Almeida MR PLoS One; 2012; 7(1):e29933. PubMed ID: 22253829 [TBL] [Abstract][Full Text] [Related]
3. Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy. Ferreira N; Saraiva MJ; Almeida MR Amyloid; 2012 Jun; 19 Suppl 1():39-42. PubMed ID: 22620965 [TBL] [Abstract][Full Text] [Related]
4. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. Cardoso I; Saraiva MJ FASEB J; 2006 Feb; 20(2):234-9. PubMed ID: 16449795 [TBL] [Abstract][Full Text] [Related]
5. Clusterin regulates transthyretin amyloidosis. Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600 [TBL] [Abstract][Full Text] [Related]
6. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy. Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615 [TBL] [Abstract][Full Text] [Related]
7. Impairment of autophagy by TTR V30M aggregates: in vivo reversal by TUDCA and curcumin. Teixeira CA; Almeida Mdo R; Saraiva MJ Clin Sci (Lond); 2016 Sep; 130(18):1665-75. PubMed ID: 27382986 [TBL] [Abstract][Full Text] [Related]
8. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis. Liang Y; Ore MO; Morin S; Wilson DJ Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799 [TBL] [Abstract][Full Text] [Related]
9. Antibody therapy for familial amyloidotic polyneuropathy. Su Y; Jono H; Torikai M; Hosoi A; Soejima K; Guo J; Tasaki M; Misumi Y; Ueda M; Shinriki S; Shono M; Obayashi K; Nakashima T; Sugawara K; Ando Y Amyloid; 2012 Jun; 19 Suppl 1():45-6. PubMed ID: 22506915 [TBL] [Abstract][Full Text] [Related]
10. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Macedo B; Batista AR; Ferreira N; Almeida MR; Saraiva MJ Biochim Biophys Acta; 2008 Sep; 1782(9):517-22. PubMed ID: 18572024 [TBL] [Abstract][Full Text] [Related]
11. Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy. Li H; Zhang Y; Cao L; Xiong R; Zhang B; Wu L; Zhao Z; Chen SD Drug Des Devel Ther; 2014; 8():2121-8. PubMed ID: 25382970 [TBL] [Abstract][Full Text] [Related]
12. Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo. Wei L; Kawano H; Fu X; Cui D; Ito S; Yamamura K; Ishihara T; Tokuda T; Higuchi K; Maeda S Amyloid; 2004 Jun; 11(2):113-20. PubMed ID: 15478467 [TBL] [Abstract][Full Text] [Related]
13. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Sousa MM; Cardoso I; Fernandes R; Guimarães A; Saraiva MJ Am J Pathol; 2001 Dec; 159(6):1993-2000. PubMed ID: 11733349 [TBL] [Abstract][Full Text] [Related]
14. Schwann cells contribute to neurodegeneration in transthyretin amyloidosis. Murakami T; Sango K; Watabe K; Niimi N; Takaku S; Li Z; Yamamura K; Sunada Y J Neurochem; 2015 Jul; 134(1):66-74. PubMed ID: 25693163 [TBL] [Abstract][Full Text] [Related]